Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
BackgroundAs a new non-factor therapy for hemophilia A (HA), real-world study of emicizumab is still scarce. This study aimed to investigate the real-world use of emicizumab in Chinese boys with HA.MethodsPatients with moderate or severe HA were enrolled at Beijing Children's Hospital. They tak...
Saved in:
Main Authors: | Guoqing Liu (Author), Kun Huang (Author), Gang Li (Author), Yingzi Zhen (Author), Zhengping Li (Author), Zhenping Chen (Author), Runhui Wu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
by: Ricardo Mesquita Camelo, et al.
Published: (2023) -
Emicizumab in the treatment of hemophilia A
by: Tijanić Ivan R., et al.
Published: (2020) -
Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
by: Zhenping Chen, et al.
Published: (2021) -
Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022) -
Budget Impact Analysis of the use of emicizumab for bleeding prophylaxis in patients with Hemophilia A with inhibitors in the Brazilian Health System
by: Nicolas Segre, et al.
Published: (2022)